Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent whole brain radiotherapy and bortezomib for brain metastasis.
Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, Lee O, Schipper M, Van Poznak C, Hamstra D, Lawrence T, Hayman J, Redman BG. Lao CD, et al. Radiat Oncol. 2013 Aug 21;8:204. doi: 10.1186/1748-717X-8-204. Radiat Oncol. 2013. PMID: 23965287 Free PMC article. Clinical Trial.
BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.
Kim MM, Parmar HA, Schipper M, Devasia T, Aryal MP, Kesari S, O'Day S, Morikawa A, Spratt DE, Junck L, Mammoser A, Hayman JA, Lawrence TS, Tsien CI, Aiken R, Goyal S, Abrouk N, Trimble M, Cao Y, Lao CD. Kim MM, et al. Among authors: lao cd. Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):478-486. doi: 10.1016/j.ijrobp.2020.02.639. Epub 2020 Mar 10. Int J Radiat Oncol Biol Phys. 2020. PMID: 32169409 Free article. Clinical Trial.
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.
Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD. Kim MM, et al. Among authors: lao cd. Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003. Transl Oncol. 2016. PMID: 27084426 Free PMC article.
Dose escalation of a curcuminoid formulation.
Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Lao CD, et al. BMC Complement Altern Med. 2006 Mar 17;6:10. doi: 10.1186/1472-6882-6-10. BMC Complement Altern Med. 2006. PMID: 16545122 Free PMC article. Clinical Trial.
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green MD, Alva AS, Lao CD. Ma VT, et al. Among authors: lao cd. Pigment Cell Melanoma Res. 2021 May;34(3):629-640. doi: 10.1111/pcmr.12944. Epub 2020 Nov 22. Pigment Cell Melanoma Res. 2021. PMID: 33128316 Free article.
Features predicting sentinel lymph node positivity in Merkel cell carcinoma.
Schwartz JL, Griffith KA, Lowe L, Wong SL, McLean SA, Fullen DR, Lao CD, Hayman JA, Bradford CR, Rees RS, Johnson TM, Bichakjian CK. Schwartz JL, et al. Among authors: lao cd. J Clin Oncol. 2011 Mar 10;29(8):1036-41. doi: 10.1200/JCO.2010.33.4136. Epub 2011 Feb 7. J Clin Oncol. 2011. PMID: 21300936 Free PMC article.
84 results